2.4 billion large varieties of Hisun will be approved for domestic sales soaring 170%

Recently, Zhejiang Hisun Pharmaceutical entered the administrative examination and approval stage with imitation of tofacitib citrate tablets for production in Category 4.

Source: official website of the State Food and Drug Administration

Tofacitinib citrate tablet is the world's first small molecule targeted JAK kinase inhibitor for rheumatoid arthritis developed by Pfizer.

Global sales of tofacitib citrate (unit: US$100 million)

Source: Mynet.

Since tofacitib citrate was approved for listing, its global sales have been increasing year by year, reaching US$2.

The original research product was approved to enter the domestic market in March 2017.

Sales of tofacitib citrate tablets in physical pharmacies in cities in China

Source: Mi Nei.

The physical pharmacy terminal in Chinese cities is one of the main sales terminals for tofacitib citrate tablets.

The new registration classification of tofacitib citrate tablets is under review

Source: Meinenet MED2.

According to data from Minai.

Source: Minei.